Schiff Antarctic Krill and Fish Oil Blend Disease Interactions
There are 2 disease interactions with Schiff Antarctic Krill and Fish Oil Blend (omega-3 polyunsaturated fatty acids).
Omega-3 fatty acids (applies to Schiff Antarctic Krill and Fish Oil Blend) arrhythmias
Moderate Potential Hazard, Moderate plausibility.
Cases of recurrent atrial fibrillation (AF) or flutter have been reported with the use of omega-3 fatty acids in patients with a symptomatic paroxysmal AF or persistent AF. This condition is more apparent within the first 2 to 3 months after the initiation of therapy. Therapy with these agents should be administered cautiously in patients with cardiac conduction disorders.
References
- (2005) "Product Information. Omacor (omega-3 polyunsaturated fatty acids)." Abbott Pharmaceutical
Omega-3 fatty acids (applies to Schiff Antarctic Krill and Fish Oil Blend) liver disease
Moderate Potential Hazard, Moderate plausibility.
Increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels have been observed in patients receiving omega-3 fatty acids. Therapy with omega-3 fatty acid preparations should be administered cautiously in patients with hepatic impairment. Serum liver enzyme levels should be monitored periodically.
References
- (2005) "Product Information. Omacor (omega-3 polyunsaturated fatty acids)." Abbott Pharmaceutical
- (2021) "Product Information. Lovaza (omega-3 polyunsaturated fatty acids)." Woodward Pharma Services, Rev. 02-2021-00
Schiff Antarctic Krill and Fish Oil Blend drug interactions
There are 72 drug interactions with Schiff Antarctic Krill and Fish Oil Blend (omega-3 polyunsaturated fatty acids).
More about Schiff Antarctic Krill and Fish Oil Blend (omega-3 polyunsaturated fatty acids)
- Schiff Antarctic Krill and Fish Oil Blend consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: nutraceutical products
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.